TCM Biotech International Corp. (TPEX:4169)

Market Cap	10.66B +220.6%
Revenue (ttm)	682.40M -8.6%
Net Income	21.08M -26.3%
EPS	0.36 -26.9%
Shares Out	59.05M
PE Ratio	505.66
Forward PE	83.18
Dividend	0.35 (0.19%)
Ex-Dividend Date	Aug 28, 2025

Volume	50,185
Average Volume	114,329
Open	181.50
Previous Close	181.50
Day's Range	178.50 - 181.50
52-Week Range	43.65 - 199.50
Beta	0.01
RSI	50.26
Earnings Date	Apr 17, 2026

About TCM Biotech International

TCM Biotech International Corp., a biotech company, engages in the research and development of drugs for liver diseases. The company offers medical devices, such as therapy for osteoarthritis, intra-articular implant of hyaluronic acid, automated blood cell separator, absorbable adhesion barrier material, prosthetic and orthotic accessory, and pellefeel mask pressure relief pad; and pharmaceuticals, including iron supplement, therapeutic agent for urinary system, expectorant/mucolytic agent, anticancer drug, antihypertensive drug, and antidiabe...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4169

Financial Performance

In 2024, TCM Biotech International's revenue was 666.53 million, a decrease of -31.26% compared to the previous year's 969.62 million. Earnings were 21.01 million, an increase of 13.12%.